Scott L Friedman - Internal Medicine | Mount Sinai

Biography

Specialties

Internal Medicine, Gastroenterology

Research Topics

Aerodigestive Tract, Anti-Tumor Therapy, Apoptosis/Cell Death, Autophagy, Biomedical Sciences, Cancer Genetics, Cell Biology, Cell Transformation, Developmental Biology, Drug Resistance, Endothelial Cells, Epithelial Cells, Extracellular Matrix, Fibrosis, Gene Regulation, Growth Factors and Receptors, Hepatitis C Virus, Integrins, Knockout Mice, Liver, Macrophage, Metastasis, Molecular Biology, Organogenesis, Oxidative Stress, Phosphorylation, Proteases, Receptors, Signal Transduction, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice, Tumor Suppressor Genes, Tumorigenesis, Vascular Development, Wound Healing

Multi-Disciplinary Training Area

Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT)

Research

Mechanisms of Hepatic Fibrosis and Cancer

Dr. Friedman is the Director of both the Division of Liver Diseaases and the Fibrosis Research Center, and is co-Director of the Tisch Cancer Institute Liver Cancer Program

Specific Clinical/Research Interest:

Cellular and molecular mechanisms of hepatic fibrosis and cancer

Diagnosis and development of anti-fibrotic therapies for patients with chronic liver disease

Clinical trials of antifibrotic therapies in patients with chronic liver disease

Current Students: Billie Bian PhD Student, Fatemah Parvin-Nejad, MD Student; Benjamin Wooden, MD Student

Current Postdoctoral Fellows: Youngjoon Yoon, MD; Takuma Tsuchida PhD;

Research Personnel: Hsin Chou, M.S. (Lab Manager); Dipankar Bhattacharya, M.S.

Summary of Research Studies:

Our work explores the molecular mechanisms of wound healing and fibrosis in liver and how they contribute to liver cancer. We use a variety of animal and cell culture models to identify key inflammatory mediatiors and signaling molecules regulating the activation of hepatic stellate cells, the principle fibrogenic cells in liver. Additionally, we test candidate antifibrotic lead compounds to develop potential new therapies for patients with chronic fibrosing liver diseases. Specific projects include:

- Molecular mechanisms of hepatic stellate cell activation and the cell's role iin hepatic regeneration, immunity and repair
-Testing of antifibrotic lead compounds in animal models
-Clinical trials of antifibrotic therapies in patients with chronic liver disease

Education

BS, Rensselaer Polytechnic Institute

MD, Icahn School of Medicine at Mount Sinai

Residency, Internal Medicine, Beth Israel Deaconess Medical Center-Main Campus

Fellowship, Gastroenterology, University of CA at San Francisco Medical Center

Certifications

American Board of Internal Medicine

Honors & Awards

2016

Am Assn for the Study of Liver Diseases Distinguished Achievement Award

AASLD

2016

American Liver Foundation Distinguished Achievement Award

American Liver Foundation

2015

Emmet B Keeffe Mentoring Award

Recognizes outstanding mentorship in the field of hepatology

2015

Fellow, American Assn for the Advancement fo Science

AAAS

2015

Maud Menten Honorary Lecture

U. Pittsburgh

2015

Burton Combes Memorial Lecture

UT Southwestern GI Division

2015

Charles Lieber Memorial Lecture

American Gastroenterological Assn

2014

China Friendship Award

Chinese Government, presented by the Premier of China

2014

The Jacobi Medallion

The Icahn School of Medicine at Mount Sinai

2014

Salute to Excellence Award

American Liver Foundation, San Francisco Chapter

2014

Fellow

Am Assn for the Study of Liver Diseases

2014

President

American Assn for the Study of Liver Diseases

2014

Rao Honorary Lecture

Feinberg School of Medicine, Northwestern U.

2013

International Recognition Award

European Assn for the Study of LIver

2013

Shanghai Magnolia Gold Award

City of Shanghai

2012

Master Educator Recognition

Mount Sinai Institute for Medical Education

2010

Englert Lecture

University of Utah Dept of Medicine

2009

Rafael Research Alumni Visiting Scientist

Rambam Hospital, Haifa, Israel

2009

Sheila Sherlock Lecture

British Assn for Gastroenterology, Liverpool, UK

2008

Ken & Louise Goldberg Visiting Professor

Brigham and Women's Hospital, Boston MA

2008

Sackler Distinguished Lectureship

Tel Aviv University, Israel

2008

Fellow of the American Gastroenterological Assn

2006

Solomon Berson Dept of Medicine Housestaff Teaching Award

2004

International Hans Popper Research Prize

Falk foundation

2003

International Hans Popper Award to Outstanding Researcher in Hepatology

1995

Fulbright Senior Scholar Award

1979

Arthur H. Aufses Sr., Prize in Surgery

Mount Sinai School of Medicine

Publications

518

Publications

Selected Publications

Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells. Kavita Prasad, Dipankar Bhattacharya, Shams Gamal Eldin Shams, Kimberly Izarraras, Tia Hart, Brent Mayfield, Maryjka B. Blaszczyk, Zhongren Zhou, Utpal B. Pajvani, Scott L. Friedman, Moshmi Bhattacharya. Cells

Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. Harrison T. Muturi, Hilda E. Ghadieh, Suman Asalla, Sumona G. Lester, Getachew D. Belew, Sobia Zaidi, Raziyeh Abdolahipour, Abhishek P. Shrestha, Agnes O. Portuphy, Hannah L. Stankus, Raghd Abu Helal, Stefaan Verhulst, Sergio Duarte, Ali Zarrinpar, Leo A. van Grunsven, Scott L. Friedman, Robert F. Schwabe, Terry D. Hinds, Sivarajan Kumarasamy, Sonia M. Najjar. Molecular Metabolism

Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction. James K. Carter, Ming Chao Tsai, Nicholas Venturini, Jiangting Hu, John J. Lemasters, Miguel Torres Martin, Daniela Sia, Shuang Wang, Youngmin A. Lee, Scott L. Friedman. Hepatology

View All Publications

Video

The Dawn of Translation in NASH and Hepatic Fibrosis

Drug, Diagnostic and Device Development: From Scientific Findings to FDA Approval

Office Locations

Icahn (East) Building Floor 11th Floor Room Room 11-70C

1425 Madison Ave

New York, NY 10029

212-659-9501

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Friedman during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Boston Pharmaceuticals
Mediar Therapeutics
AGED Diagnostics
Takeda Pharmaceuticals Of North America, Inc.
InSitro
Pfizer Pharmaceuticals
HepGene
Ochre Bio
RAPT Therapeutics, Inc.
Junevity
Merck & Co., Inc.
89bio Inc
Boehringer Ingelheim, Ltd.
Laekna
Macomics
Kriya
Satellite Bio
Scholar Rock
Morphic Therapeutic
Engine Biosciences
Gordian Biotechnology
Surrozen
Acceler, Korea
Variant BIo
AgoMab
Carisma Therapeutics
Overtone Therapeutics
Sagimet Biosciences
Therasid Bio
Korro BIo
Wrench Bio
Resolution Therapeutics
Incendia Therapeutics
North Sea Therapeutics
Arda Therapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Mediar Therapeutics
Satellite Bio
AGED Diagnostics
Scholar Rock
InSitro
Morphic Therapeutic
Gordian Biotechnology
Surrozen
HepGene
Ochre Bio
Junevity
Sagimet Biosciences
Laekna
North Sea Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Friedman during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

Boston Pharmaceuticals
Mediar Therapeutics
AGED Diagnostics
Takeda Pharmaceuticals Of North America, Inc.
InSitro
Pfizer Pharmaceuticals
HepGene
Ochre Bio
RAPT Therapeutics, Inc.
Junevity
Merck & Co., Inc.
89bio Inc
Boehringer Ingelheim, Ltd.
Laekna
Macomics
Kriya
Satellite Bio
Scholar Rock
Morphic Therapeutic
Engine Biosciences
Gordian Biotechnology
Surrozen
Acceler, Korea
Variant BIo
AgoMab
Carisma Therapeutics
Overtone Therapeutics
Sagimet Biosciences
Therasid Bio
Korro BIo
Wrench Bio
Resolution Therapeutics
Incendia Therapeutics
North Sea Therapeutics
Arda Therapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

Mediar Therapeutics
Satellite Bio
AGED Diagnostics
Scholar Rock
InSitro
Morphic Therapeutic
Gordian Biotechnology
Surrozen
HepGene
Ochre Bio
Junevity
Sagimet Biosciences
Laekna
North Sea Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.